Radiopharm Theranostics Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Net Income	-	-38.34	-47.95	-34.61	-30.42
Depreciation & Amortization	-	2.6	3.13	3.3	2.98
Stock-Based Compensation	-	1.9	2.64	3.04	4.8
Other Adjustments	-	3.09	12.15	1.13	10.48
Change in Receivables	-	-9.41	3.48	1.51	-0.05
Changes in Accounts Payable	-	0.51	3.5	2.35	2.53
Changes in Other Operating Activities	-21.95	-33.7	-22.9	-23.11	-10.14
Operating Cash Flow	-36.87	-36.65	-22.98	-23.2	-9.91
Capital Expenditures	-	-	-	-0.05	-0
Purchases of Intangible Assets	-	-	-	-	-28.34
Proceeds from Sale of Intangible Assets	-	3	-	-1.49	-
Purchases of Investments	-	-	-	-	-0.04
Other Investing Activities	-	-1.23	-0.32	-	-
Investing Cash Flow	-	1.77	-0.32	-1.53	-28.38
Long-Term Debt Issued	-	-	7.37	-	0.01
Long-Term Debt Repaid	-	-3.59	-5.17	-	-0.07
Net Long-Term Debt Issued (Repaid)	-	-3.59	2.2	-	-0.06
Issuance of Common Stock	-	53.98	29.65	10.07	70
Net Common Stock Issued (Repurchased)	-	53.98	29.65	10.07	70
Other Financing Activities	-0.76	-4.96	-1.65	-0.85	-4.83
Financing Cash Flow	-1.04	45.43	30.2	9.22	65.11
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.32	-0.01	-0.03	0.23	0.13
Net Cash Flow	-38.23	10.56	6.9	-15.51	26.82
Free Cash Flow	-36.87	-36.65	-22.98	-23.25	-9.91
FCF Margin	-	-1008.57%	-7678.40%	-7951.56%	-
Free Cash Flow Per Share	-4.02	-5.28	-17.84	-22.80	-16.40
Levered Free Cash Flow	-21.95	-72.52	-62.02	-52.12	-35.1
Unlevered Free Cash Flow	-21.95	-68.86	-63.58	-52.03	-25.68

SEC Filings: 10-K · 10-Q